TLDR
- BioAffinity stock jumps 123% as CyPath® Lung sales surge in 2025
- CyPath® Lung adoption rises as physician network expands 67%
- bioAffinity raises $16.9M to scale lung cancer diagnostic growth
- Longitudinal CyPath® Lung trial launches with 2,000 patient target
- Pipeline diagnostics for asthma and COPD advance toward 2026 studies
BIAF shares surged sharply during the latest trading session following the company’s annual financial update. The stock traded near $2.3969, gaining 123.67% intraday. The move reflected strong trading momentum after the company outlined expanding demand for its lung cancer diagnostic platform.
bioAffinity Technologies, Inc., BIAF
The biotechnology company focuses on noninvasive diagnostics designed to detect lung cancer earlier. Its CyPath® Lung test remains the central driver of the company’s commercialization strategy. Operational restructuring during 2025 redirected resources toward expanding the diagnostic’s market reach.
Management also highlighted several clinical, financial, and operational milestones that shaped the year. These developments included rising physician adoption and expanded intellectual property protection. Consequently, the company positioned its diagnostic platform for broader clinical integration and growth.
CyPath Lung Drives Commercial Momentum
CyPath Lung generated strong commercial traction during 2025 as demand increased across physician networks. Revenue from the diagnostic rose 87% compared with the previous year. Additionally, the number of tests performed increased 99% year over year.
The company also expanded the number of physician offices ordering the test. The network of clinics using CyPath Lung grew 67% during the year. Greater peer-to-peer engagement among physicians helped drive awareness and clinical adoption.
BioAffinity also streamlined operations at its Precision Pathology Laboratory Services unit. The company discontinued several unprofitable pathology services during the year. As a result, the strategy concentrated operational resources on scaling CyPath® Lung nationwide.
Financial Results Reflect Strategic Transition
BioAffinity reported total revenue of $6.2 million for 2025. Revenue declined from $9.4 million in 2024 due to discontinued pathology services. However, the company reported strong growth in diagnostic testing revenue.
Operating expenses declined nine percent to $16.7 million during the year. The reduction resulted from targeted cost controls and streamlined laboratory operations. Research and development spending totaled $1.4 million as the company continued diagnostic pipeline development.
The company recorded a net loss of $14.9 million for the year. The loss increased from $9.0 million in 2024. The company strengthened its financial position through multiple equity financings during 2025.
2026 Expansion and Clinical Development Plans
BioAffinity entered 2026 with plans to accelerate adoption of its diagnostic platform. The company expects CyPath Lung unit sales to increase more than 100% compared with 2025. Revenue growth should follow as the company expands geographic coverage and physician partnerships.
The company also launched a longitudinal clinical trial in early 2026. The study will enroll up to 2,000 high-risk patients with indeterminate pulmonary nodules. Seventeen military, academic, and private medical centers will participate in the program.
The trial will evaluate diagnostic sensitivity and specificity during a two-year follow-up period. The John P. Murtha Cancer Center Research Program supports the study at several federal facilities. The program may provide additional clinical validation for broader market adoption.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
